Impact of Omega-3 Fatty Acid Supplementation in Parenteral Nutrition on Inflammatory Markers and Clinical Outcomes in Critically Ill COVID-19 Patients: A Randomized Controlled Trial

source extracted confidence: high 2026-04-09
#humans #parenteral-nutrition #male #fatty-acids-omega-3 #female

Impact of Omega-3 Fatty Acid Supplementation in Parenteral Nutrition on Inflammatory Markers and Clinical Outcomes in Critically Ill COVID-19 Patients: A Randomized Controlled Trial

Berlana et al., 2024 | Nutrients | Rct

Citation

Berlana David, Albertos Raquel, ... Ferrer-Costa Roser. Impact of Omega-3 Fatty Acid Supplementation in Parenteral Nutrition on Inflammatory Markers and Clinical Outcomes in Critically Ill COVID-19 Patients: A Randomized Controlled Trial. Nutrients. 2024-Sep-10;16(18). doi:10.3390/nu16183046

Abstract

The heightened inflammatory response observed in COVID-19 patients suggests that omega-3 fatty acids (O3FA) may confer anti-inflammatory benefits. This randomized, double-blind, single-center clinical trial aimed to evaluate the effect of O3FA supplementation in parenteral nutrition (PN) on inflammatory markers in COVID-19 patients admitted to the intensive care unit (ICU). A total of 69 patients were randomized into three groups: one received standard lipid emulsion, and two received O3FA (Omegaven®) at doses of 0.1 g/kg/day and 0.2 g/kg/day, respectively, in addition to Smoflipid®. The primary outcomes measured were serum levels of C-reactive protein (CRP) and interleukin-6 (IL-6) on days 1, 5, and 10 of PN initiation. Secondary outcomes included additional inflammatory markers (TNF-α, IFN-γ, IL-1Ra, CXCL10), hepatic function, triglyceride levels, and clinical outcomes such as mortality and length of ICU and hospital stay. Results indicated a significant reduction in CRP, IL-6, and CXCL10 levels in the group receiving 0.1 g/kg/day O3FA compared to the control. Additionally, the higher O3FA dose was associated with a shorter ICU and hospital stay. These findings suggest that O3FA supplementation in PN may reduce inflammation and improve clinical outcomes in critically ill COVID-19 patients.

Key Findings

These findings suggest that O3FA supplementation in PN may reduce inflammation and improve clinical outcomes in critically ill COVID-19 patients.

Outcomes Measured

  • C-reactive protein
  • inflammatory markers

Population

Field Value
Population See abstract
Sample Size 19
Age Range See abstract
Condition inflammation

MeSH Terms

  • Humans
  • Parenteral Nutrition
  • Male
  • Fatty Acids, Omega-3
  • Female
  • Critical Illness
  • Middle Aged
  • COVID-19
  • Double-Blind Method
  • C-Reactive Protein
  • Dietary Supplements
  • Aged
  • Biomarkers
  • Inflammation
  • Intensive Care Units
  • Treatment Outcome
  • Interleukin-6
  • SARS-CoV-2
  • Length of Stay

Evidence Classification

  • Level: Rct
  • Publication Types: Journal Article, Randomized Controlled Trial
  • Vertical: omega-3-inflammation

Provenance

Source extracted via PubMed E-utilities API on 2026-04-09